TF-MAPS: fast high-resolution functional and allosteric mapping of DNA-binding proteins
5 affiliations
- 1Wellcome Sanger Institute, Cambridge, UK
- 2King’s College London, London, UK
- 3Centre for Genomic Regulation (CRG), Barcelona Institute for Science and Technology (BIST), Barcelona, Spain
- 4Universitat Pompeu Fabra (UPF), Barcelona, Spain
- 5Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
Abstract
Transcription factors (TFs) bind specific DNA sequences to control gene expression. Modulating TF activity is of considerable therapeutic interest but very few TFs have been drugged successfully. TF DNA-binding interfaces are large and most TFs have no known allosteric ligands or allosteric sites. Here we introduce TF-MAPs, a scalable and general platform to chart complete functional maps of sequence-specific DNA-binding proteins. We apply TF-MAPS to three human disease TFs: HNF1A, FOXG1 and FOXP1. Allostery in all three proteins is distance-dependent, anisotropic and couples the DNA-binding interface to the protein surface. The allosteric surfaces of FOXG1 and FOXP1 are quite diverged, revealing a potential for protein-specific regulation in protein families. All three TFs have potentially druggable small pockets where mutations affect DNA binding, either within the binding interface or distant from it. Application of TF-MAPS will potentially lead to charting functional and allosteric maps for hundreds of human TFs and other DNA-binding proteins to understand DNA recognition and TF regulation, to interpret clinical variants mechanistically and to guide the development of TF-modulating therapeutics.
Related
- GPCR-MAPS: high-resolution functional and allosteric mapping of G-protein-coupled receptor activation functions and bias
- Cholesterol Hot Spot Automated Mapping Protocol (CHAMP): Identifying Cholesterol-Binding Hot Spots in Membrane Proteins.
- VAEBAC: a representation-learning framework for proteome-scale prediction of amyloidogenic proteins and functional stratification of nucleic-acid-binding proteins.
- Beyond the ATP-binding pocket: emerging strategies in kinase targeting from allosteric inhibition to targeted protein degradation
- Fragment-based drug discovery strategy reveals an unprecedented allosteric binding site in Mycobacterium tuberculosis DNA gyrase
BibTeX
@article{li2026tfmaps,
title = {{TF-MAPS: fast high-resolution functional and allosteric mapping of DNA-binding proteins}},
author = {Xianghua Li and Ben Lehner},
journal = {Nature Structural \& Molecular Biology},
year = {2026},
month = nov,
doi = {10.1038/s41594-026-01908-2},
url = {https://doi.org/10.1038/s41594-026-01908-2},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - TF-MAPS: fast high-resolution functional and allosteric mapping of DNA-binding proteins
AU - Xianghua Li
AU - Ben Lehner
PY - 2026
DA - 2026/11/11
JO - Nature Structural & Molecular Biology
DO - 10.1038/s41594-026-01908-2
UR - https://doi.org/10.1038/s41594-026-01908-2
AB - Transcription factors (TFs) bind specific DNA sequences to control gene expression. Modulating TF activity is of considerable therapeutic interest but very few TFs have been drugged successfully. TF DNA-binding interfaces are large and most TFs have no known allosteric ligands or allosteric sites. Here we introduce TF-MAPs, a scalable and general platform to chart complete functional maps of sequence-specific DNA-binding proteins. We apply TF-MAPS to three human disease TFs: HNF1A, FOXG1 and FOXP1. Allostery in all three proteins is distance-dependent, anisotropic and couples the DNA-binding interface to the protein surface. The allosteric surfaces of FOXG1 and FOXP1 are quite diverged, revealing a potential for protein-specific regulation in protein families. All three TFs have potentially druggable small pockets where mutations affect DNA binding, either within the binding interface or distant from it. Application of TF-MAPS will potentially lead to charting functional and allosteric maps for hundreds of human TFs and other DNA-binding proteins to understand DNA recognition and TF regulation, to interpret clinical variants mechanistically and to guide the development of TF-modulating therapeutics.
SN - 1545-9993
SN - 1545-9985
ER -